0001104659-24-036143.txt : 20240319 0001104659-24-036143.hdr.sgml : 20240319 20240319161322 ACCESSION NUMBER: 0001104659-24-036143 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240315 FILED AS OF DATE: 20240319 DATE AS OF CHANGE: 20240319 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SAPIRSTEIN JAMES CENTRAL INDEX KEY: 0001559509 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37853 FILM NUMBER: 24763353 MAIL ADDRESS: STREET 1: 1517 SAN JACINTO CITY: HOUSTON STATE: TX ZIP: 77002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: First Wave BioPharma, Inc. CENTRAL INDEX KEY: 0001604191 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464993860 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 BUSINESS PHONE: 561-589-7020 MAIL ADDRESS: STREET 1: 777 YAMATO ROAD STREET 2: SUITE 502 CITY: BOCA RATON STATE: FL ZIP: 33431 FORMER COMPANY: FORMER CONFORMED NAME: AzurRx BioPharma, Inc. DATE OF NAME CHANGE: 20141103 FORMER COMPANY: FORMER CONFORMED NAME: BioPharma d'Azur, Inc. DATE OF NAME CHANGE: 20140331 4 1 tm249257-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-03-15 0 0001604191 First Wave BioPharma, Inc. FWBI 0001559509 SAPIRSTEIN JAMES C/O FIRST WAVE BIOPHARMA, INC 777 YAMATO ROAD, SUITE 502 BOCA RATON FL 33431 1 1 0 0 Chairman and CEO 0 Common Stock 2024-03-15 4 S 0 1887 4.96 D 37279 D The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.90 - $5.175, inclusive. The Reporting Person undertakes to provide First Wave BioPharma, Inc. ("First Wave"), any security holder of First Wave, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Includes unvested RSUs. /s/ James Sapirstein 2024-03-19